ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
ANI Pharmaceuticals (ANIP) PT Raised to $73 at Raymond James
February 28, 2019 7:42 AM ESTRaymond James analyst Elliot Wilbur raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $73.00 (from $63.00) while maintaining a Strong Buy rating following another strong quarter.
Wilbur said they believe the outperformance in 4Q18 as well as solid initial 2019 guidance... More
ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
February 27, 2019 8:34 AM ESTANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.32, $0.08 better than the analyst estimate of $1.24. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $53.48 million.
For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46Adjusted non-GAAP EBITDA of $22.2 millionAdjusted non-GAAP diluted earnings per share of $1.32Arthur... More
